Microsatellite Instability and Metastatic Colorectal Cancer - A Clinical Perspective

Area of Science:

• Oncology
• Cancer Immunology
• Gastrointestinal Oncology

Background:

• Metastatic colorectal cancer (mCRC) with mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) comprises 4-5% of cases.
• These tumors exhibit variable responses to standard chemotherapy and targeted therapies.
• Recent advances show significant benefits of immunotherapy with checkpoint inhibitors for dMMR/MSI-H mCRC.

Purpose of the Study:

• To review the current landscape of immunotherapy for dMMR/MSI-H mCRC.
• To identify challenges and unanswered questions in optimizing treatment strategies.
• To explore potential future directions for improving patient outcomes.

Main Methods:

• Review of recent clinical trials and scientific literature.
• Analysis of treatment responses and outcomes in dMMR/MSI-H mCRC patients.
• Discussion of emerging biomarkers and combination therapy approaches.

Main Results:

• Immunotherapy, specifically checkpoint inhibitors, has demonstrated dramatic long-term benefits in clinical trials for dMMR/MSI-H mCRC.
• The response to conventional therapies like fluoropyrimidine-based chemotherapy is often variable in this patient subgroup.
• Significant questions remain regarding the optimization of immunotherapy regimens and patient selection.

Conclusions:

• Immunotherapy represents a breakthrough for dMMR/MSI-H mCRC, offering substantial long-term benefits.
• Optimizing immunotherapy regimens and identifying predictive biomarkers are crucial next steps.
• Combination strategies and maintenance immunotherapy post-induction therapy may enhance outcomes.